Cue Biopharma Inc (NAS:CUE)
$ 1.69 -0.17 (-9.09%) Market Cap: 101.75 Mil Enterprise Value: 93.22 Mil PE Ratio: 0 PB Ratio: 3.78 GF Score: 64/100

Q4 2022 Cue Biopharma Inc Earnings Call Transcript

Mar 21, 2023 / 08:30PM GMT
Release Date Price: $3.38 (+9.39%)
Operator

Greetings, and welcome to the Cue Biopharma Fourth Quarter and Full Year 2022 Earnings Call.

(Operator Instructions)

As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Dan Passeri, Chief Executive Officer. Please go ahead.

Daniel R. Passeri
Cue Biopharma, Inc. - CEO & Director

Yes. Thank you, and good afternoon, everyone. As a reminder, this conference will be recorded and available on our website for the next 30 days. Also as a reminder, those listening in, just be aware of the webcast, you need to advance the slides as you are listening, and we'll notify you which slide we're on at a given time.

Joining me on today's call is Dr. Matteo Levisetti, our Chief Medical Officer; Dr. Ken Pienta, now in the role as a Clinical Advisory Cue; Dr. Anish Suri, our President and Chief Scientific Officer; and Kerri Millar, Chief Financial Officer. Also joining us briefly on today's call is Dr. Sara Pai, surgical oncologist and Director of Translational Head and Neck Cancer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot